Clinical response in advanced non-small cell lung cancer with high PD-L1 expression and MET exon 14 skipping mutation: a case analysis of overcoming immunotherapy resistance and literature review - Top-Institutions - MDSpire

Clinical response in advanced non-small cell lung cancer with high PD-L1 expression and MET exon 14 skipping mutation: a case analysis of overcoming immunotherapy resistance and literature review

  • By

  • Yefei Ruan

  • Lin Qiu

  • May 12, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Hospital Universitario
    Hospital Universitario

    Unknown, Unknown

    Key Differentiators

    • Oncology

  • #2

    Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute
    Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology

  • #3

    Institut Gustave Roussy
    Institut Gustave Roussy

    Villejuif, France

    Key Differentiators

    • Oncology

Original Source(s)

Clinical response in advanced non-small cell lung cancer with high PD-L1 expression and MET exon 14 skipping mutation: a case analysis of overcoming immunotherapy resistance and literature review

  • by Yefei Ruan, Lin Qiu

  • May 12, 2026

Related Content

Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma

Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort